Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 18/20 | 0.64 |
| ▸ | CA2 | P00918 | 18/20 | 0.64 |
| ▸ | CA12 | O43570 | 14/20 | 0.64 |
| ▸ | CA9 | Q16790 | 14/20 | 0.64 |
| ▸ | CA4 | P22748 | 8/20 | 0.64 |
| ▸ | CA6 | P23280 | 7/20 | 0.64 |
| ▸ | CA5A | P35218 | 7/20 | 0.64 |
| ▸ | CA7 | P43166 | 7/20 | 0.64 |
| ▸ | CA14 | Q9ULX7 | 7/20 | 0.64 |
| ▸ | CA5B | Q9Y2D0 | 7/20 | 0.64 |
| ▸ | CA3 | P07451 | 6/20 | 0.64 |
| ▸ | CA13 | Q8N1Q1 | 6/20 | 0.61 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5014186 | 0.95 | CA1 (0.70) | CA1CA2CA12CA9CA4 | |
| SCHEMBL3500908 | 0.89 | CA1 (0.56) | CA1CA2CA12CA9CA4 | |
| SCHEMBL1806519 | 0.83 | CA1 (0.76) | CA1CA2CA12CA9CA4 | |
| SCHEMBL3267605 | 0.81 | CA12 (0.56) | CA1CA2CA12CA9CA4 | |
| SCHEMBL20485809 | 0.81 | CA1 (0.55) | CA1CA2CA12CA9CA4 | |
| SCHEMBL1806516 | 0.81 | CA1 (0.55) | CA1CA2CA12CA9CA4 | |
| SCHEMBL11554555 | 0.81 | CA1 (0.61) | CA1CA2CA12CA9CA4 | |
| SCHEMBL1807804 | 0.80 | CA1 (0.79) | CA1CA2CA12CA9CA4 | |
| SCHEMBL11132234 | 0.80 | CA1 (0.79) | CA1CA2CA12CA9CA4 | |
| SCHEMBL5245480 | 0.80 | CA1 (0.55) | CA1CA2CA12CA9CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1385507-A4 | SULFONAMIDES | SMITHKLINE BEECHAM CORP (US) | 2005-11-23 | — | — | EP | claimed |
| EP-1385507-A1 | SULFONAMIDES | SmithKline Beecham Corporation (US) | 2004-02-04 | — | — | EP | claimed |
| WO-2002089792-A1 | SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-11-14 | — | — | WO | claimed |
| US-20090253683-A1 | 7-MEMBERED RING COMPOUND AND METHOD OF PRODUCTION AND PHARMACEUTICAL APPLICATION THEREOF | ASUBIO PHARMA CO., LTD (JP) | 2009-10-08 | — | — | US | disclosed |
| US-20060004010-A1 | Ccr4 antagonist and medical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-05 | — | — | US | disclosed |
| EP-1541563-A1 | CCR4 ANTAGONIST AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004080389-A2 | HYDROXYEICOSADIENAMIDE COMPOUNDS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2004-09-23 | — | — | WO | disclosed |
| US-6774212-B2 | FOR THERAPY OF VIRAL INFECTION OR AS AN ASSAY STANDARD OR REAGENT | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-08-10 | — | — | US | disclosed |
| EP-1252178-A1 | ALPHA-KETOAMIDE INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | Bristol-Myers Squibb Pharma Company (US) | 2002-10-30 | — | — | EP | disclosed |
| US-20020123468-A1 | Alpha-ketoamide inhibitors of hepatitis C virus NS3 protease | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-09-05 | — | — | US | disclosed |
| WO-2001040262-A1 | ALPHA-KETOAMIDE INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-06-07 | — | — | WO | disclosed |
| US-4486603-A | Preparation of trans cyclohexane 1,4-diamine | AKZONA INCORPORATED (US) | 1984-12-04 | — | — | US | disclosed |
| US-4439370-A | Preparation of trans cyclohexane 1,4-diisocyanate | AKZONA INCORPORATED (US) | 1984-03-27 | — | — | US | disclosed |
| US-4275223-A | Preparation of trans-cyclohexane-1,4-diurethanes | AKZONA INCORPORATED (US) | 1981-06-23 | — | — | US | disclosed |
| US-4203916-A | Preparation of trans cyclohexane 1,4 diisocyanate | AKZONA INCORPORATED (US) | 1980-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004010-A1 | Ccr4 antagonist and medical use thereof | CCR4, CCR1, CCR9 | CA1 838/4885CA2 743/4885CA12 667/4885 |
| US-20090253683-A1 | 7-MEMBERED RING COMPOUND AND METHOD OF PRODUCTION AND PHARMACEUTICAL APPLICATION THEREOF | CMA1, CPA3, SI | CA1 418/4885CA2 187/4885CA12 352/4885 |
| US-20020123468-A1 | Alpha-ketoamide inhibitors of hepatitis C virus NS3 protease | CES1, CYP51A1, SPINT2 | CA1 695/4885CA2 869/4885CA12 810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.